Lucas M, Sánchez-Soliño O, Solano F, Izquierdo G
Molecular Biology Service of the Virgen Macarena University Hospital, Seville, Spain.
Neurochem Int. 1998 Aug;33(2):101-2. doi: 10.1016/s0197-0186(98)00014-x.
We studied the rate of reactive oxygen species (ROS) production by monocytes 'ex vivo' in a cohort of healthy individuals, in a group of MS patients undergoing treatment with interferon beta-1b and another group of MS patients who refused treatment with interferon beta-1b. The rate of ROS production in healthy individuals was slightly lower than in non-treated MS patients. The lower rate of ROS production was obtained in monocytes of MS patients treated with interferon beta-1b. These results indicate that the treatment of relapsing-remitting MS patients with interferon beta-1b rendered the NADPH oxidase of the monocytes less sensitive to trigger reactive oxygen species (ROS).
我们在一组健康个体、一组接受β-1b干扰素治疗的多发性硬化症（MS）患者以及另一组拒绝β-1b干扰素治疗的MS患者中，对单核细胞“离体”产生活性氧（ROS）的速率进行了研究。健康个体中ROS的产生速率略低于未治疗的MS患者。在用β-1b干扰素治疗的MS患者的单核细胞中，ROS的产生速率更低。这些结果表明，用β-1b干扰素治疗复发缓解型MS患者可使单核细胞的NADPH氧化酶对触发活性氧（ROS）的敏感性降低。
